In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States

World Journal of Microbiology and Biotechnology

Volumn 29, Issue 2, 2013, Pages 347-354

  Liu, Xiaoqiang ^a,b   Boothe, Dawn M ^b   Jin, Yaping ^a   Thungrat, Kamoltip ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Canine; Escherichia coli; Feline; Fluoroquinolone; MIC; MPC

Indexed keywords

ANTIBIOTICS; ESCHERICHIA COLI;

CANINE; FELINE; FLUOROQUINOLONES; FLUOROQUINOLONES (FQS); GEOMETRIC MEAN; MINIMUM INHIBITORY CONCENTRATION; PATHOGENIC ESCHERICHIA COLI; URINARY TRACT INFECTIONS;

MICROWAVE INTEGRATED CIRCUITS;

ESCHERICHIA COLI; FELIDAE;

EID: 84874216830     PISSN: 09593993     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11274-012-1188-x     Document Type: Article

References (28)

1. Authier S, Paquette D, Labrecque O, Messier S (2006) Comparison of susceptibility to antimicrobials of bacterial isolates from companion animals in a veterinary diagnostic laboratory in Canada between 2 time points 10 years apart. Can Vet J 47: 774-778.
2. Ball P (2000) Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46(Suppl T1): 17-24.
3. Blondeau JM, Zhao X, Hansen G, Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 433-438.
4. Boothe DM (2006) Pharmacokinetic and pharmacodynamic indices of pradofloxacin efficacy in canine serum, and subcutaneous interstitial fluid, presented as a final report to Bayer Animal Health. Germany, Berlin.
5. Boothe DM, Boeckh A, Boothe HW, Wilkie S, Jones S (2002) Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7. 5, 10, or 20 mg/kg. Vet Ther 3: 409-419.
6. Boothe DM, Boeckh A, Simpson RB, Dubose K (2006) Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 20: 1297-1306.
7. CLSI (2008) Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents: approved guideline (3rd edn) (ISBN Number 1-56238-660-3). CLSI Document M37-A3. Clinical Laboratory Standards Institute, Wayne, PA, USA.
8. CLSI (2012) Performance standards for antimicrobial susceptiblity testing; twenty-second informational supplement (ISBN 1-56238-785-5). CLSI Document M100-S22. Clinical Laboratory Standards Institute Wayne, PA, USA.
9. Cohn LA, Gary AT, Fales WH, Madsen RW (2003) Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J Vet Diagn Invest 15: 338-343.
10. Cooke CL, Singer RS, Jang SS, Hirsh DC (2002) Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J Am Vet Med Assoc 220: 190-192.
11. Drlica K, Schmitz FJ (2002) Therapeutic options in an era of decreasing antimicrobial susceptibility. J Chemother 14(Suppl 2): 5-12.
12. EMEA/CVMP (2007) Refusal CVMP assessment report for veraflox. Eur Med Agency Vet Med 342257 Inspe 1-37.
13. EUCAST (2011) Breakpoint tables for interpretation of MICs and zone diameters. European committee on antimicrobial susceptibility testing. Version 1. 3, pp 1-68.
14. Hombach M, Bloemberg GV, Bottger EC (2012) Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 67: 622-632.
15. Hopkins KL, Davies RH, Threlfall EJ (2005) Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 25: 358-373.
16. Ince D, Hooper DC (2001) Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 45: 2755-2764.
17. Institute CaLS (2008) Performance standards for antimicrobial disk and dilution susceptibility testing for bacteria isolated from animals; approved standard (3rd edn). CLSI Document M31-A3 28.
18. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ (2003) Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136: 500-505.
19. Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X (2011) Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 55: 2409-2412.
20. Liu X, Boothe DM, Thungrat K, Aly S (2012) Mechanisms accounting for fluoroquinolone multidrug resistance Escherichia coli isolated from companion animals. Vet Microbiol (in press).
21. Marcusson LL, Olofsson SK, Komp Lindgren P, Cars O, Hughes D (2005) Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55: 938-943.
22. Martinez M, McDermott P, Walker R (2006) Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J 172: 10-28.
23. Normand EH, Gibson NR, Reid SW, Carmichael S, Taylor DJ (2000) Antimicrobial-resistance trends in bacterial isolates from companion-animal community practice in the UK. Prev Vet Med 46: 267-278.
24. Pasquali F, Manfreda G (2007) Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, SalmonellaTyphimurium and Pseudomonas aeruginosa. Vet Microbiol 119: 304-310.
25. Scoper SV (2008) Review of third-and fourth-generation fluoroquinolones in ophthalmology: in vitro and in vivo efficacy. Adv Ther 25: 979-994.
26. Shaheen BW, Boothe DM, Oyarzabal OA, Wang C, Johnson CM (2011) Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats. Am J Vet Res 72: 25-32.
27. Sindelar G, Zhao X, Liew A, Dong Y, Lu T, Zhou J, Domagala J, Drlica K (2000) Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 44: 3337-3343.
28. Wetzstein HG (2005) Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother 49: 4166-4173.